Market Acquisition ProtaTek International was acquired by Pharmgate LLC in 2016, indicating potential opportunities to offer complementary biotech solutions or integrate products that support their vaccine development and manufacturing efforts.

Niche Expertise Specialized in developing vaccines for swine, ProtaTek operates within the veterinary biotechnology sector, providing a targeted entry point for suppliers of animal health ingredients, biotech equipment, or veterinary testing services.

Growth Potential With an annual revenue estimated between 1 million and 10 million and a relatively small team, there is significant scope to expand product offerings or services aimed at biotech startups and research organizations in their regional and industry network.

Technology Stack Utilization of advanced platforms like Microsoft Azure and open-source tools suggests openness to technological partnerships, cloud services, and biotech data management solutions for enhancing R&D and operational efficiency.

Regional Presence Located in Saint Paul, Minnesota, a hub for biotech innovation, ProtaTek can serve as a strategic partner for companies seeking local manufacturing, research collaborations, or regional distribution in the veterinary biotech market.